The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma

References

• J M B, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA)[J]. Nat Rev Gastroenterol Hepatol. 2016;13(5):261–280.
   PubMed Web of Science ®Google Scholar
• J M B, J J G M, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588.
   PubMed Web of Science ®Google Scholar
• Rizvi S, S A K, C L H, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol. 2018;15(2):95–111.
   PubMed Web of Science ®Google Scholar
• L DM, S C C, J L C, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution[J]. Ann Surg. 2007;245(5):755–762.
   PubMed Web of Science ®Google Scholar
• Nakeeb A, H A P, T A S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors[J]. Ann Surg. 1996;224(4):463–473. discussion 473-5.
   PubMed Web of Science ®Google Scholar
• Lindnér P, Rizell M, Hafström L. The impact of changed strategies for patients with cholangiocarcinoma in this millenium[J]. HPB Surg. 2015;2015:736049.
   PubMedGoogle Scholar
• Kamsa-Ard S, Luvira V, Suwanrungruang K, et al. Cholangiocarcinoma trends, incidence, and relative survival in Khon Kaen, Thailand from 1989 through 2013: a population-based cancer registry study[J]. J Epidemiol. 2019;29(5):197–204.
   PubMed Web of Science ®Google Scholar
• Vallejo A, Erice O, Entrialgo-Cadierno R, et al. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted[J]. J Hepatol. 2021;75(2):363–376.
   PubMed Web of Science ®Google Scholar
• Marti P, Stein C, Blumer T, et al. YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors[J]. Hepatology. 2015;62(5):1497–1510.
   PubMed Web of Science ®Google Scholar
• Isomoto H, Kobayashi S, Werneburg NW, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells[J]. Hepatology. 2005;42(6):1329–1338.
   PubMed Web of Science ®Google Scholar
• Liu L, Wu J, Guo Y, et al. Overexpression of FoxM1 predicts poor prognosis of intrahepatic cholangiocarcinoma[J]. Aging (Albany NY). 2018;10(12):4120–4140.
   PubMedGoogle Scholar
• Sobolev VV, Khashukoeva AZ, Evina OE, et al. Role of the transcription factor FOSL1 in organ development and tumorigenesis[J]. Int J Mol Sci. 2022;23(3):1521.
   PubMed Web of Science ®Google Scholar
• Matsumori T, Kodama Y, Takai A, et al. Hes1 is essential in proliferating ductal cell-mediated development of intrahepatic cholangiocarcinoma[J]. Cancer Res. 2020;80(23):5305–5316.
   PubMed Web of Science ®Google Scholar
• Boerner T, Drill E, Pak LM, et al. Genetic determinants of outcome in cholangiocarcinoma[J]. Hepatology. 2021;74(3):1429–1444.
   PubMed Web of Science ®Google Scholar
• Yoshino J, Akiyama Y, Shimada S, et al. Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma[J]. Carcinogenesis. 2020;41(6):734–742.
   PubMed Web of Science ®Google Scholar
• Dachrut S, Banthaisong S, Sripa M, et al. DNA copy-number loss on 1p36.1 harboring RUNX3 with promoter hypermethylation and associated loss of RUNX3 expression in liver fluke-associated intrahepatic cholangiocarcinoma[J]. Asian Pac J Cancer Prev. 2009;10(4):575–582.
   PubMedGoogle Scholar
• Khaenam P, Niibori A, Okada S, et al. Contribution of RIZ1 to regulation of proliferation and migration of a liver fluke-related cholangiocarcinoma cell[J]. Asian Pac J Cancer Prev. 2012;13(8):4007–4011.
   PubMedGoogle Scholar
• Lozano E, Asensio M, Perez-Silva L, et al. MRP3-mediated chemoresistance in cholangiocarcinoma: target for chemosensitization through restoring SOX17 expression[J]. Hepatology. 2020;72(3):949–964.
   PubMed Web of Science ®Google Scholar
• Dana P, Saisomboon S, Kariya R, et al. CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion[J]. Cell Oncol (Dordr). 2020;43(2):211–222.
   PubMed Web of Science ®Google Scholar
• Armartmuntree N, Murata M, Techasen A, et al. Prolonged oxidative stress down-regulates Early B cell factor 1 with inhibition of its tumor suppressive function against cholangiocarcinoma genesis[J]. Redox Biol. 2018;14:637–644.
   PubMed Web of Science ®Google Scholar
• Chiang NJ, S SY, Hung WC, et al. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma[J]. Int J Biochem Cell Biol. 2015;67:110–114.
   PubMed Web of Science ®Google Scholar
• Merino-Azpitarte M, Lozano E, J PM, et al. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma[J]. J Hepatol. 2017;67(1):72–83.
   PubMed Web of Science ®Google Scholar
• W YX, Li L, J HG, et al. STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome[J]. Oncotarget. 2017;8(5):7710–7721.
   PubMedGoogle Scholar
• Tian F, Li D, Chen J, et al. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma[J]. Eur J Cancer. 2013;49(7):1771–1780.
   PubMed Web of Science ®Google Scholar
• He J, Gerstenlauer M, K CL, et al. Block of NF-kB signaling accelerates MYC-driven hepatocellular carcinogenesis and modifies the tumor phenotype towards combined hepatocellular cholangiocarcinoma[J]. Cancer Lett. 2019;458:113–122.
   PubMed Web of Science ®Google Scholar
• Lambert M, Jambon S, Depauw S, et al. Targeting transcription factors for cancer treatment[J]. Molecules. 2018;23(6):1479.
   PubMed Web of Science ®Google Scholar
• M VJ, K KS, A TS, et al. A census of human transcription factors: function, expression and evolution[J]. Nat Rev Genet. 2009;10(4):252–263.
   PubMed Web of Science ®Google Scholar
• Lambert SA, Jolma A, F CL, et al. The human transcription factors[J]. Cell. 2018;172(4):650–665
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Papavassiliou AG. Seeing the future of cancer-associated transcription factor drug targets[J]. Jama. 2011;305(22):2349–2350.
   PubMed Web of Science ®Google Scholar
• Li H, Wolfe A, Septer S, et al. Deregulation of hippo kinase signalling in human hepatic malignancies[J]. Liver Int. 2012;32(1):38–47.
   PubMed Web of Science ®Google Scholar
• Tao J, F CD, Ranganathan S, et al. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice[J]. Gastroenterology. 2014;147(3):690–701.
   PubMed Web of Science ®Google Scholar
• Pei T, Li Y, Wang J, et al. YAP is a critical oncogene in human cholangiocarcinoma[J]. Oncotarget. 2015;6(19):17206–17220.
   PubMedGoogle Scholar
• Wu H, Liu Y, W JX, et al. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma[J]. Tumour Biol. 2016;37(10):13499–13508.
   PubMedGoogle Scholar
• Lee K, Lee KB, Y JH, et al. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas[J]. BMC Cancer. 2017;17(1):441.
   PubMedGoogle Scholar
• Zhang Y, Xu H, Cui G, et al. β-catenin sustains and is required for YES-associated protein oncogenic activity in cholangiocarcinoma[J]. Gastroenterology. 2022;163(2):481–494.
   PubMed Web of Science ®Google Scholar
• Bharadwaj U, M KM, Robinson P, et al. Targeting janus kinases and signal transducer and activator of transcription 3 to Treat inflammation, fibrosis, and cancer: rationale, progress, and caution[J]. Pharmacol Rev. 2020;72(2):486–526.
   PubMed Web of Science ®Google Scholar
• Puigdevall L, Michiels C, Stewardson C, et al. JAK/STAT: why choose a classical or an alternative pathway when you can have both?[J]. J Cell Mol Med. 2022;26(7):1865–1875.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhu B, Zhao L, et al. Allicin inhibits proliferation and invasion in vitro and in vivo via SHP-1-mediated STAT3 signaling in cholangiocarcinoma[J]. Cell Physiol Biochem. 2018;47(2):641–653.
   PubMedGoogle Scholar
• R BB, L SR, F BS, et al. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2[J]. Hepatology. 2009;50(6):1861–1870.
   PubMed Web of Science ®Google Scholar
• Saengboonmee C, Seubwai W, Cha’on U, et al. Metformin exerts antiproliferative and anti-metastatic effects against cholangiocarcinoma cells by targeting STAT3 and NF-ĸB[J]. Anticancer Res. 2017;37(1):115–123.
   PubMed Web of Science ®Google Scholar
• B AB, Sethi G, S AK, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution[J]. Ann N Y Acad Sci. 2006;1091(1):151–169.
   PubMedGoogle Scholar
• Zheng T, Hong X, Wang J, et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma[J]. Hepatology. 2014;59(3):935–946.
   PubMed Web of Science ®Google Scholar
• Golson ML, Kaestner KH. Fox transcription factors: from development to disease[J]. Development. 2016;143(24):4558–4570.
   PubMed Web of Science ®Google Scholar
• Yokomine K, Senju S, Nakatsura T, et al. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy[J]. Int J Cancer. 2010;126(9):2153–2163.
   PubMed Web of Science ®Google Scholar
• Detarya M, Thaenkaew S, Seubwai W, et al. High glucose upregulates FOXM1 expression via EGFR/STAT3 dependent activation to promote progression of cholangiocarcinoma[J]. Life Sci. 2021;271:119114.
   PubMed Web of Science ®Google Scholar
• Chan-On W, T HN, Songtawee N, et al. Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells[J]. Drug Des Devel Ther. 2015;9:2033–2047.
   PubMed Web of Science ®Google Scholar
• Yang L, Feng S, Yang Y. Identification of transcription factors (TFs) and targets involved in the cholangiocarcinoma (CCA) by integrated analysis[J]. Cancer Gene Ther. 2016;23(12):439–445.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun R, Zhang X, et al. Transcription factor 7 promotes the progression of perihilar cholangiocarcinoma by inducing the transcription of c-Myc and FOS-like antigen 1[J]. EBioMedicine. 2019;45:181–191.
   PubMed Web of Science ®Google Scholar
• Gu Y, Xiao L, Ming Y, et al. Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo[J]. Int J Oncol. 2016;48(5):1868–1876.
   PubMed Web of Science ®Google Scholar
• Peng T, Deng X, Tian F, et al. The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma[J]. Int J Oncol. 2019;55(3):657–670.
   PubMed Web of Science ®Google Scholar
• Deng X, Jiang P, Chen J, et al. GATA6 promotes epithelial-mesenchymal transition and metastasis through MUC1/β-catenin pathway in cholangiocarcinoma[J]. Cell Death Dis. 2020;11(10):860.
   PubMed Web of Science ®Google Scholar
• Samatiwat P, Prawan A, Senggunprai L, et al. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents[J]. Tumour Biol. 2016;37(8):11495–11507.
   PubMedGoogle Scholar
• Samatiwat P, Prawan A, Senggunprai L, et al. Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells[J]. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(6):601–612.
   PubMed Web of Science ®Google Scholar
• Chen Q, Li W, Wan Y, et al. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways[J]. Hepatology. 2012;55(6):1820–1829.
   PubMed Web of Science ®Google Scholar
• Guan L, Zhang L, Gong Z, et al. FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1-Nrf2 signaling[J]. Hepatology. 2016;63(6):1914–1927.
   PubMed Web of Science ®Google Scholar
• H WZ, Y JT, Y SY, et al. RPB5-mediating protein promotes cholangiocarcinoma tumorigenesis and drug resistance by competing with NRF2 for KEAP1 binding[J]. Hepatology. 2020;71(6):2005–2022.
   PubMed Web of Science ®Google Scholar
• He H, Sinha I, Fan R, et al. c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer[J]. Oncogene. 2018;37(19):2586–2600.
   PubMed Web of Science ®Google Scholar
• Wolter S, Doerrie A, Weber A, et al. c-Jun controls histone modifications, NF-kappaB recruitment, and RNA polymerase II function to activate the ccl2 gene[J]. Mol Cell Biol. 2008;28(13):4407–4423.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Wirka R, Nguyen T, et al. TCF21 and AP-1 interact through epigenetic modifications to regulate coronary artery disease gene expression[J]. Genome Med. 2019;11(1):23.
   PubMedGoogle Scholar
• He K, Feng Y, An S, et al. Integrative epigenomic profiling reveal AP-1 is a key regulator in intrahepatic cholangiocarcinoma[J]. Genomics. 2022;114(1):241–252.
   PubMed Web of Science ®Google Scholar
• Zhang D, Li H, Jiang X, et al. Role of AP-2α and MAPK7 in the regulation of autocrine TGF-β/miR-200b signals to maintain epithelial-mesenchymal transition in cholangiocarcinoma[J]. J Hematol Oncol. 2017;10(1):170.
   PubMedGoogle Scholar
• Choodetwattana P, Proungvitaya S, Jearanaikoon P, et al. The upregulation of OCT4 in acidic extracellular pH is associated with gemcitabine resistance in cholangiocarcinoma cell lines[J]. Asian Pac J Cancer Prev. 2019;20(9):2745–2748.
   PubMedGoogle Scholar
• Lu M, Qin X, Zhou Y, et al. Long non-coding RNA LINC00665 promotes gemcitabine resistance of cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis[J]. Cell Death Dis. 2021;12(1):72.
   PubMed Web of Science ®Google Scholar
• Duncan CJA, Hambleton S. Human disease phenotypes associated with loss and gain of function mutations in STAT2: viral susceptibility and type I interferonopathy[J]. J Clin Immunol. 2021;41(7):1446–1456.
   PubMed Web of Science ®Google Scholar
• Huang Z, Yu C, Yu L, et al. The roles of FHL3 in cancer[J]. Front Oncol. 2022;12:887828.
   PubMed Web of Science ®Google Scholar
• Tan X, Tong L, Li L, et al. Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation[J]. Nat Commun. 2021;12(1):4853.
   PubMed Web of Science ®Google Scholar
• Kastenhuber ER, Lowe SW. Putting p53 in context[J]. Cell. 2017;170(6):1062–1078.
   PubMed Web of Science ®Google Scholar
• Limpaiboon T, Krissadarak K, Sripa B, et al. Microsatellite alterations in liver fluke related cholangiocarcinoma are associated with poor prognosis[J]. Cancer Lett. 2002;181(2):215–222.
   PubMed Web of Science ®Google Scholar
• Jusakul A, Cutcutache I, H YC, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma[J]. Cancer Discov. 2017;7(10):1116–1135.
   PubMed Web of Science ®Google Scholar
• M RP, D RS, Portmann B, et al. p53 protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis[J]. Gut. 1996;38(2):265–268.
   PubMed Web of Science ®Google Scholar
• M BK, Schrumpf E, Bergquist A, et al. Cholangiocarcinoma in primary sclerosing cholangitis: k-ras mutations and Tp53 dysfunction are implicated in the neoplastic development[J]. J Hepatol. 2000;32(3):374–380.
   PubMed Web of Science ®Google Scholar
• M MS, Y BJ, Koszarek A, et al. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss[J]. Hepatology. 2012;55(1):121–131.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xin B, Yamamoto M, et al. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice[J]. Cancer Sci. 2021;112(8):3111–3124.
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Koldobskiy MA, Göndör A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression[J]. Nat Rev Genet. 2016;17(5):284–299.
   PubMed Web of Science ®Google Scholar
• O’rourke CJ, Lafuente-Barquero J, Andersen JB. Epigenome remodeling in cholangiocarcinoma[J]. Trends Cancer. 2019;5(6):335–350.
   PubMed Web of Science ®Google Scholar
• Jiao Y, M PT, A AR, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas[J]. Nat Genet. 2013;45(12):1470–1473.
   PubMed Web of Science ®Google Scholar
• Mathur R. ARID1A loss in cancer: towards a mechanistic understanding[J]. Pharmacol Ther. 2018;190:15–23.
   PubMed Web of Science ®Google Scholar
• Z YS, Q WA, Du J, et al. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma[J]. World J Gastroenterol. 2016;22(25):5814–5821.
   PubMed Web of Science ®Google Scholar
• Zou S, Li J, Zhou H, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014;5(1):5696.
   PubMed Web of Science ®Google Scholar
• Farshidfar F, Zheng S, C GM, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles[J]. Cell Rep. 2017;18(11):2780–2794.
   PubMed Web of Science ®Google Scholar
• Sriraksa R, Zeller C, A E-BM, et al. CpG-island methylation study of liver fluke-related cholangiocarcinoma[J]. Br J Cancer. 2011;104(8):1313–1318.
   PubMed Web of Science ®Google Scholar
• H PJ, C SW, B SS, et al. Peroxiredoxin 6 expression is inversely correlated with nuclear factor-κB activation during Clonorchis sinensis infestation[J]. Free Radic Biol Med. 2016;99:273–285.
   PubMed Web of Science ®Google Scholar
• Harder L, Eschenburg G, Zech A, et al. Aberrant ZNF423 impedes B cell differentiation and is linked to adverse outcome of ETV6-RUNX1 negative B precursor acute lymphoblastic leukemia[J]. J Exp Med. 2013;210(11):2289–2304.
   PubMed Web of Science ®Google Scholar
• Armartmuntree N, Jusakul A, Sakonsinsiri C, et al. Promoter hypermethylation of early B cell factor 1 (EBF1) is associated with cholangiocarcinoma progression[J]. J Cancer. 2021;12(9):2673–2686.
   PubMed Web of Science ®Google Scholar
• Lee MJ, R YG, J YH, et al. ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma[J]. Gastroenterology. 2009;137(3):1138–50, 1150.e1–9.
   Web of Science ®Google Scholar
• Lu D, Han C, Wu T. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression[J]. Gastroenterology. 2011;140(7):2084–2094.
   PubMed Web of Science ®Google Scholar
• Shen J, Zhou Y, Zhang X, et al. Loss of FoxA2 accelerates neoplastic changes in the intrahepatic bile duct partly via the MAPK signaling pathway[J]. Aging (Albany NY). 2019;11(21):9280–9294.
   PubMedGoogle Scholar
• You Z, Xu J, Li B, et al. The mechanism of ATF3 repression of epithelial-mesenchymal transition and suppression of cell viability in cholangiocarcinoma via p53 signal pathway[J]. J Cell Mol Med. 2019;23(3):2184–2193.
   PubMed Web of Science ®Google Scholar
• Kam AE, Masood A, Shroff RT. Current and emerging therapies for advanced biliary tract cancers[J]. Lancet Gastroenterol Hepatol. 2021;6(11):956–969.
   PubMed Web of Science ®Google Scholar
• K A-AG, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J]. Lancet Oncol. 2020;21(5):671–684.
   PubMed Web of Science ®Google Scholar
• Stadhouders R, Filion GJ, Graf T. Transcription factors and 3D genome conformation in cell-fate decisions[J]. Nature. 2019;569(7756):345–354.
   PubMed Web of Science ®Google Scholar
• Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy[J]. Nat Rev Clin Oncol. 2021;18(10):645–661.
   PubMed Web of Science ®Google Scholar
• Bushweller JH. Targeting transcription factors in cancer - from undruggable to reality[J]. Nat Rev Cancer. 2019;19(11):611–624.
   PubMed Web of Science ®Google Scholar